Context: Insufficient efficacy and safety data for off-label use of aromatase inhibitors to augment height in boys with short stature.
Objective: To compare anastrozole and letrozole in treatment of idiopathic short stature in pubertal boys.
Design: Open-label trial with 2 treatment arms.
Setting: Pediatric Endocrine Clinic at Stanford.
Participants: A total of 79 pubertal males ≥10 years with bone age (BA) ≤ 14 years, predicted adult height (PAH) < 5th percentile or >10 cm below mid-parental height.
Intervention: Anastrozole 1.0 mg or letrozole 2.5 mg daily for up to 3 years.
Main Outcome Measures: Annual hormone levels and growth parameters during treatment and a year posttherapy; annual BA and PAH (primary outcome measure); spine x-rays and dual energy X-ray absorptiometry at baseline and 2 years.
Results: Compared with anastrozole (n = 35), letrozole (n = 30) resulted in higher testosterone levels, lower estradiol and IGF-1 levels, and slower growth velocity and BA advance. The PAH increase observed at year 1 in both groups did not persist at years 2 and 3. Change in PAH from baseline was not different between treatment groups. In groups combined, PAH gain over 3 years vs baseline was +1.3 cm ( = .043) in linear mixed models.
Conclusion: Letrozole caused greater deviations than anastrozole in hormone levels, growth velocity, and BA advancement, but no group differences in PAH or side effects were found. Change in PAH after 2 to 3 years of treatment was minimal. The efficacy of AI as monotherapy for height augmentation in pubertal boys with idiopathic short stature may be limited, and safety remains an issue.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11388000 | PMC |
| http://dx.doi.org/10.1210/jendso/bvae141 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System.
Cancer Med
January 2025
Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, Georgia, USA.
Introduction: Emerging evidence suggests potential cardiovascular toxicities from oral endocrine therapies (ETs); however, results are conflicting. This study comprehensively examined adverse reactions of ETs and investigated cardiovascular and metabolic safety signals within the FDA Adverse Event Reporting System (FAERS).
Methods: Reports in the FAERS through December 2023 were analyzed for documented reactions to tamoxifen, letrozole, anastrozole, and exemestane in female breast cancer patients.
Targeted and cytotoxic inhibitors used in the treatment of breast cancer.
Pharmacol Res
December 2024
Blue Ridge Institute for Medical Research, 221 Haywood Knolls Drive, Hendersonville, NC 28791, United States. Electronic address:
Breast cancer is the most commonly diagnosed malignancy and the fifth leading cause of cancer deaths worldwide. Surgery and radiation therapy are localized therapies for early-stage and metastatic breast cancer. The management of breast cancer is determined in large part by the HER2 (human epidermal growth factor receptor 2), HR (hormone receptor), ER (estrogen receptor), and PR (progesterone receptor) status.
View Article and Find Full Text PDFThree sample preparation methods for clinical determination of CDK4/6 inhibitors with endocrine therapy in breast cancer patient plasma using LC-MS: Cross-validation (red), ecological (green) and economical (blue) assessment.
J Pharm Biomed Anal
November 2024
University of Zagreb Faculty of Pharmacy and Biochemistry, Department of Pharmaceutical Analysis, Ante Kovačića 1, Zagreb, Croatia. Electronic address:
Article Synopsis
- Cyclin D-dependent kinase 4/6 inhibitors, along with aromatase inhibitors and estrogen receptor degraders, are being evaluated for their effectiveness in therapeutic drug monitoring due to a lack of routine clinical methods.
- This study assesses three sample preparation techniques: dispersive liquid-liquid microextraction (DLLME), solid-phase extraction (SPE), and phospholipid removal (PLR), for accurately measuring these drugs in patient plasma.
- Results show that all methods are highly precise and accurate, with DLLME being the most eco-friendly, PLR allowing for high throughput, and SPE offering superior analytical performance, enabling users to choose the best method based on their needs.
Aromatase Inhibitor Monotherapy to Augment Height in Boys: Does It Work and Is It Safe?
J Endocr Soc
October 2024
Children's Hospital Los Angeles, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.
Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial.
Oncol Res Treat
November 2024
Medical Department, iOMEDICO, Freiburg, Germany.
Introduction: The INGE-B trial (NCT02894398) aimed to confirm the efficacy and safety data from the PALOMA trials for patients treated first line (1L) with palbociclib (PAL) and letrozole or 1L and later line with PAL and fulvestrant. In addition, so far lacking evidence for efficacy and safety on the combination of PAL with anastrozole, exemestane (1L), or letrozole (later line) was investigated.
Methods: The prospective, multicenter, multicohort phase 2 trial INGE-B enrolled adult patients with locally advanced, inoperable, or metastatic HR+/HER2- breast cancer in Germany.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!